Compare ARLO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | BEAM |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2018 | 2020 |
| Metric | ARLO | BEAM |
|---|---|---|
| Price | $14.38 | $25.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $24.00 | ★ $48.09 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $509,572,000.00 | $55,701,000.00 |
| Revenue This Year | $4.65 | N/A |
| Revenue Next Year | $7.87 | $19.01 |
| P/E Ratio | $421.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.84 | $13.53 |
| 52 Week High | $19.94 | $35.25 |
| Indicator | ARLO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 59.27 |
| Support Level | $12.81 | $20.23 |
| Resistance Level | $13.70 | $22.72 |
| Average True Range (ATR) | 0.58 | 1.66 |
| MACD | 0.01 | 0.45 |
| Stochastic Oscillator | 48.90 | 96.90 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.